Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
AACE Endocrinology and Diabetes · 2026-05 · 13 (3) · 400-409
DOI: 10.1016/j.aed.2026.03.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift AACE Endocrinology and Diabetes, 2026-05. Verfasst von Naseem Eisa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Community Health Partners, Fresno, California. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The association between incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and thyroid cancer risk remains controversial. Conflicting observational findings highlight the need for evidence derived exclusively from randomized controlled trials (RCTs).
Objectives
To evaluate the association between incretin-based therapies and thyroid cancer risk using RCT data.
Methods
We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, EMBASE, and ClinicalTrials.gov were searched through January 4, 2026, for RCTs of approved incretin-based therapies with ≥26 weeks of follow-up that reported thyroid cancer events. Data extraction was performed independently by 2 reviewers. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Pooled odds ratios and 95% CIs were calculated using a random-effects model. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation framework.
Results
Fifteen RCTs enrolling 84 237 participants were included. Across all trials, 28 thyroid cancer events occurred in the incretin-based therapy groups and 15 in the control groups. Meta-analysis showed no statistically significant association between incretin-based therapy use and thyroid cancer risk (odds ratio 1.52, 95% CI 0.86-2.68; I2 = 0.0%). Findings were consistent across prespecified subgroup and sensitivity analyses. Certainty of evidence was rated very low due to serious imprecision related to rare events.
Conclusions
RCT evidence does not demonstrate a statistically significant increase in thyroid cancer risk with incretin-based therapies. However, limited follow-up and imprecision prevent exclusion of a clinically relevant increase, supporting the need for long-term surveillance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Community Health Partners, Fresno, California.
- Faculty of Medicine, Damascus University, Damascus, Syria.
Zitieren
APA
Eisa, N., & Barood, O. (2026). Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. AACE Endocrinology and Diabetes, 13(3), 400-409. https://doi.org/10.1016/j.aed.2026.03.003
Vancouver
Eisa N, Barood O. Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. AACE Endocrinology and Diabetes. 2026;13(3):400-409. doi:10.1016/j.aed.2026.03.003
BibTeX
@article{Eisa2026,
author = {Eisa, Naseem and Barood, Omar},
title = {Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {3},
pages = {400--409},
doi = {10.1016/j.aed.2026.03.003}
}
EUVIMED